HR Execs on the Move


 
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.foamix.com
  • 520 U.S. Highway 22 Suite 204
    Bridgewater, NJ USA 08807
  • Phone: 800.775.7936

Executives

Name Title Contact Details

Similar Companies

Pinnacle Pharmaceutics

Pinnacle Pharmaceutics Ltd is a Whitby, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Regulatory and Clinical Research Institute

Regulatory & Clinical Research Institute, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

DM Clinical Research

DM Clinical Research is a clinical research company that connects pharmaceutical and research organizations to individuals seeking to power the advancement of medicine. They specialize in multiple therapeutic areas in Phase I-IV clinical trials.

Fischer Imaging

Manufactures programmable E/P stimulators. The Company manufactures a full line of programmable E/P stimulators to accommodate the needs of cardiologists. The Company also develops, manufactures and markets a diagnostic x-ray and digital radiography sy...

Sun Pharma

Sun Pharma is the world`s fourth largest specialty generic pharmaceutical company and India`s top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma`s global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.